Regeneron Pharmaceuticals (REGN)

• Market cap: $78.3B
• 1 day: -0.76%
• 5 days: -1.57%
• 1 month: -4.49%
• 3 months: 14.17%
• 6 months: 33.56%
• Year to date: -3.98%
• 1 year: 8.47%
• 5 years: 47.95%
• 10 years: 77.45%
• Sector: Healthcare
• Industry: Biotechnology

About: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Employees: 15,207